CO5390073A1 - Forma de dosificacion oral solida de simeticona - Google Patents
Forma de dosificacion oral solida de simeticonaInfo
- Publication number
- CO5390073A1 CO5390073A1 CO02087102A CO02087102A CO5390073A1 CO 5390073 A1 CO5390073 A1 CO 5390073A1 CO 02087102 A CO02087102 A CO 02087102A CO 02087102 A CO02087102 A CO 02087102A CO 5390073 A1 CO5390073 A1 CO 5390073A1
- Authority
- CO
- Colombia
- Prior art keywords
- dosage form
- simethicone
- adsorbent
- simeticone
- oral dosage
- Prior art date
Links
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 title abstract 5
- 239000006186 oral dosage form Substances 0.000 title 1
- 229950002273 simeticone Drugs 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 239000003463 adsorbent Substances 0.000 abstract 4
- 229940083037 simethicone Drugs 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- 239000007909 solid dosage form Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/966,441 US7101573B2 (en) | 2001-09-28 | 2001-09-28 | Simethicone solid oral dosage form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5390073A1 true CO5390073A1 (es) | 2004-04-30 |
Family
ID=25511414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO02087102A CO5390073A1 (es) | 2001-09-28 | 2002-09-27 | Forma de dosificacion oral solida de simeticona |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7101573B2 (enExample) |
| EP (1) | EP1297825B1 (enExample) |
| AR (1) | AR036700A1 (enExample) |
| AT (1) | ATE296619T1 (enExample) |
| AU (1) | AU2002301259C1 (enExample) |
| BR (1) | BR0204001A (enExample) |
| CA (1) | CA2405190C (enExample) |
| CO (1) | CO5390073A1 (enExample) |
| DE (1) | DE60204403T2 (enExample) |
| DK (1) | DK1297825T3 (enExample) |
| ES (1) | ES2243664T3 (enExample) |
| HU (1) | HUP0203176A2 (enExample) |
| MX (1) | MXPA02009570A (enExample) |
| NZ (1) | NZ521657A (enExample) |
| PL (1) | PL204141B1 (enExample) |
| PT (1) | PT1297825E (enExample) |
| RU (1) | RU2362569C2 (enExample) |
| ZA (1) | ZA200207755B (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632429B1 (en) | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
| US8012504B2 (en) * | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
| US7985420B2 (en) * | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
| US6955821B2 (en) | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
| US7838032B2 (en) * | 2000-04-28 | 2010-11-23 | Reckitt Benckiser Inc. | Sustained release of guaifenesin |
| US20070053895A1 (en) * | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
| US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| US7101573B2 (en) * | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
| US7179488B2 (en) | 2001-11-29 | 2007-02-20 | Bob Sherwood | Process for co-spray drying liquid herbal extracts with dry silicified MCC |
| EP1509204A4 (en) * | 2001-11-29 | 2005-07-13 | Rettenmaier & Soehne Gmbh & Co | AGGLOMERATED PARTICLES WITH AN ACTIVE SUBSTANCE PREPARED WITH MELTED MICROCRYSTALLINE CELLULOSE |
| SE0200895D0 (sv) * | 2002-03-22 | 2002-03-22 | Astrazeneca Ab | New pharmaceutical composition |
| US7341742B2 (en) * | 2002-09-30 | 2008-03-11 | L. Perrigo Company | Simethicone containing tablet composition and method |
| EP1563837A1 (en) * | 2004-02-03 | 2005-08-17 | Ferrer Internacional, S.A. | Hypocholesterolemic compositions comprising a statin and an antiflatulent agent |
| CA2559239C (en) * | 2004-04-13 | 2021-04-06 | Boehringer Ingelheim International Gmbh | Use of simethicone and sodium picosulphate in constipated patients suffering from bloated feeling and gas discomfort during the night |
| WO2005105102A1 (en) * | 2004-05-04 | 2005-11-10 | Equitech Corporation | Improved nsaid composition |
| US20060024409A1 (en) * | 2004-07-29 | 2006-02-02 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
| US20060024384A1 (en) * | 2004-07-29 | 2006-02-02 | Giordano John A | Compositions and methods for nutrition supplementation |
| US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
| EP1862184A4 (en) * | 2005-03-24 | 2012-12-19 | Daiichi Sankyo Co Ltd | PHARMACEUTICAL COMPOSITION |
| BRPI0615607A2 (pt) * | 2005-08-30 | 2011-05-24 | Lek Pharmaceuticals | composição farmacêutica compreendendo perindopril ou seus sais |
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| KR101252635B1 (ko) * | 2006-04-20 | 2013-04-10 | (주)아모레퍼시픽 | 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제 |
| US20080015260A1 (en) * | 2006-07-13 | 2008-01-17 | Kiel Laboratories, Inc. | Pharmaceutical compositions having improved stability and methods for preparation and use |
| US20080038410A1 (en) * | 2006-08-18 | 2008-02-14 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
| AU2007317561A1 (en) | 2006-10-27 | 2008-05-15 | The Curators Of The University Of Missouri | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same |
| WO2008056200A1 (en) * | 2006-11-10 | 2008-05-15 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of simethicone |
| WO2008064192A2 (en) | 2006-11-21 | 2008-05-29 | Mcneil-Ppc, Inc. | Modified release analgesic suspensions |
| US9833510B2 (en) * | 2007-06-12 | 2017-12-05 | Johnson & Johnson Consumer Inc. | Modified release solid or semi-solid dosage forms |
| US20090004248A1 (en) * | 2007-06-29 | 2009-01-01 | Frank Bunick | Dual portion dosage lozenge form |
| AU2009215514B9 (en) | 2008-02-20 | 2014-01-30 | The Curators Of The University Of Missouri | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| US11016104B2 (en) | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
| GB2480773B (en) | 2009-01-06 | 2013-12-11 | Curelon Llc | Compositions for the treatment of diarrhea caused by virulent E. coli infections |
| EP3064217B1 (en) | 2009-01-06 | 2018-04-18 | Galenagen, LLC | Compositions comprising protease, amylase and lipase for use in the treatment of staphylococcus aureus infections |
| US20100247586A1 (en) * | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
| JP5410819B2 (ja) * | 2009-04-09 | 2014-02-05 | ライオン株式会社 | 木クレオソート含有固形製剤 |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| WO2011050135A1 (en) | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
| EP3305317B1 (en) | 2011-04-21 | 2020-06-24 | Curemark, LLC | Compounds for the treatment of neuropsychiatric disorders |
| US10463611B2 (en) * | 2011-06-08 | 2019-11-05 | Sti Pharma, Llc | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration |
| BR112014004879B1 (pt) | 2011-09-08 | 2020-01-28 | Novartis Ag | uso de inibidor de aromatase para tratamento de hipogonadismo e doenças relacionadas, composição farmacêutica oral, e kit |
| IN2014DN03373A (enExample) * | 2011-10-27 | 2015-06-05 | Borody Thomas J | |
| ITMI20112221A1 (it) * | 2011-12-05 | 2013-06-06 | Altergon Sa | Formulazioni stabili in capsule di gelatina molle di antiaggreganti piastrinici, acidi grassi omega-3 e amilosio |
| CA2858821A1 (en) | 2011-12-14 | 2013-06-27 | Disphar International B.V. | Simethicone formulation |
| RU2491941C1 (ru) * | 2011-12-27 | 2013-09-10 | Вадим Алексеевич Козловский | Композиционный энтеросорбент |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| GB201506755D0 (en) | 2015-04-21 | 2015-06-03 | Reckitt Benckiser Llc | Novel pharmaceutical formulation |
| MA41620A (fr) | 2015-05-14 | 2018-01-09 | Abdi Ibrahim Ilac Sanayi Ve Ticaret A S | Composition pharmaceutique comprenant de la siméthicone et de l'otilonium |
| JP6724537B2 (ja) * | 2015-05-26 | 2020-07-15 | 大正製薬株式会社 | 固形製剤 |
| US10166185B2 (en) * | 2015-06-09 | 2019-01-01 | J. Rettenmaier & Söhne Gmbh + Co Kg | Excipient and oral solid dosage forms for oily drugs |
| WO2016201119A1 (en) * | 2015-06-09 | 2016-12-15 | J. Rettenmaier & Söhne Gmbh + Co Kg | Excipient and oral solid dosage forms for oily drugs |
| WO2016200345A1 (en) | 2015-06-12 | 2016-12-15 | Santa Farma İlaç Sanayi̇ A. Ş. | Oral pharmaceutical composition comprising otilonium bromide and simethicone with certain bulk density and improved dissolution characteristics. |
| US11278506B2 (en) | 2015-10-09 | 2022-03-22 | Rb Health (Us) Llc | Pharmaceutical formulation |
| MX385008B (es) * | 2016-12-14 | 2025-03-14 | Rhein Siegfried Sa De Cv | Composicion mejorada de lansoprazol y simeticona y procesos para prepararla. |
| WO2018191233A1 (en) | 2017-04-10 | 2018-10-18 | Curemark, Llc | Compositions for treating addiction |
| JP7282753B2 (ja) | 2017-09-29 | 2023-05-29 | ジョンソン アンド ジョンソン コンシューマー インコーポレイテッド | 固体シメチコン粒子及びその剤形 |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
| FR3117780B1 (fr) * | 2020-12-22 | 2024-04-05 | Oreal | Composition anhydre sous forme de poudre compacte comprenant un sel de magnesium et de la cellulose microcristalline |
| CN116159032A (zh) * | 2023-03-31 | 2023-05-26 | 成都恒瑞制药有限公司 | 盐酸西替利嗪片及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56169622A (en) * | 1980-06-03 | 1981-12-26 | Kissei Pharmaceut Co Ltd | Method of making solid preparation from oily substance |
| US4744987A (en) * | 1985-03-08 | 1988-05-17 | Fmc Corporation | Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation |
| US4851226A (en) * | 1987-11-16 | 1989-07-25 | Mcneil Consumer Products Company | Chewable medicament tablet containing means for taste masking |
| US4906478A (en) * | 1988-12-12 | 1990-03-06 | Valentine Enterprises, Inc. | Simethicone/calcium silicate composition |
| US5275822A (en) * | 1989-10-19 | 1994-01-04 | Valentine Enterprises, Inc. | Defoaming composition |
| US5073384A (en) * | 1989-10-19 | 1991-12-17 | Valentine Enterprises, Inc. | Maltodextrin/defoaming composition combinate |
| NZ235876A (en) | 1989-11-01 | 1992-06-25 | Mcneil Ppc Inc | Pharmaceutical compositions containing effective amount of antidiarrheal composition and antiflatulent effective amount of simethicone |
| US5075114A (en) * | 1990-05-23 | 1991-12-24 | Mcneil-Ppc, Inc. | Taste masking and sustained release coatings for pharmaceuticals |
| CA2068402C (en) * | 1991-06-14 | 1998-09-22 | Michael R. Hoy | Taste mask coatings for preparation of chewable pharmaceutical tablets |
| JP3177707B2 (ja) | 1991-10-08 | 2001-06-18 | 堀井薬品工業株式会社 | 消化管内ガス除去剤 |
| EP0642344B1 (en) * | 1992-04-30 | 1997-03-19 | Schering Corporation | Stable hydrated cephalosporin dry powder for oral suspension formulation |
| GR1002332B (el) * | 1992-05-21 | 1996-05-16 | Mcneil-Ppc Inc. | Νεες φαρμακευτικες συνθεσεις που περιεχουν σιμεθεικονη. |
| CA2110313C (en) * | 1992-12-01 | 2004-10-26 | Edward John Roche | Pharmaceutical compositions containing a guanidinothiazole compound and antacids |
| FR2705966B1 (fr) * | 1993-06-04 | 1995-08-25 | Dow Corning Sa | Compositions antimousse utiles notamment pour le traitement de troubles gastriques. |
| JPH09504293A (ja) * | 1993-10-28 | 1997-04-28 | ザ、プロクター、エンド、ギャンブル、カンパニー | マグネシウムアルミニウムシリケート及び複数の活性成分を含有した速溶解性剤形 |
| EP0659403B1 (en) | 1993-12-15 | 2001-03-14 | National Starch and Chemical Investment Holding Corporation | Use of oil adsorbent natural polymer for cosmetic and pharmaceutical applications |
| IL116674A (en) * | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
| US6106865A (en) * | 1995-01-09 | 2000-08-22 | Edward Mendell Co., Inc. | Pharmaceutical excipient having improved compressibility |
| US5585115A (en) * | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| US6103260A (en) * | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
| WO1999063969A1 (en) * | 1998-06-08 | 1999-12-16 | Groenewoud Pieter J | Stabilized thyroxine medications |
| US6126967A (en) | 1998-09-03 | 2000-10-03 | Ascent Pediatrics | Extended release acetaminophen particles |
| US7101573B2 (en) * | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
-
2001
- 2001-09-28 US US09/966,441 patent/US7101573B2/en not_active Expired - Lifetime
-
2002
- 2002-09-25 CA CA2405190A patent/CA2405190C/en not_active Expired - Fee Related
- 2002-09-26 HU HU0203176A patent/HUP0203176A2/hu unknown
- 2002-09-26 ZA ZA200207755A patent/ZA200207755B/xx unknown
- 2002-09-27 EP EP02256741A patent/EP1297825B1/en not_active Expired - Lifetime
- 2002-09-27 CO CO02087102A patent/CO5390073A1/es not_active Application Discontinuation
- 2002-09-27 NZ NZ521657A patent/NZ521657A/en unknown
- 2002-09-27 PL PL356358A patent/PL204141B1/pl unknown
- 2002-09-27 DE DE60204403T patent/DE60204403T2/de not_active Expired - Lifetime
- 2002-09-27 AR ARP020103669A patent/AR036700A1/es not_active Application Discontinuation
- 2002-09-27 AU AU2002301259A patent/AU2002301259C1/en not_active Ceased
- 2002-09-27 ES ES02256741T patent/ES2243664T3/es not_active Expired - Lifetime
- 2002-09-27 PT PT02256741T patent/PT1297825E/pt unknown
- 2002-09-27 DK DK02256741T patent/DK1297825T3/da active
- 2002-09-27 RU RU2002125821/15A patent/RU2362569C2/ru not_active IP Right Cessation
- 2002-09-27 AT AT02256741T patent/ATE296619T1/de not_active IP Right Cessation
- 2002-09-27 MX MXPA02009570A patent/MXPA02009570A/es active IP Right Grant
- 2002-09-30 BR BR0204001-8A patent/BR0204001A/pt not_active Application Discontinuation
-
2006
- 2006-07-28 US US11/460,741 patent/US7691409B2/en not_active Expired - Lifetime
-
2010
- 2010-02-03 US US12/699,129 patent/US20100135982A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR036700A1 (es) | 2004-09-29 |
| RU2002125821A (ru) | 2004-03-27 |
| ZA200207755B (en) | 2004-03-26 |
| US20100135982A1 (en) | 2010-06-03 |
| PL356358A1 (en) | 2003-04-07 |
| EP1297825A1 (en) | 2003-04-02 |
| US7101573B2 (en) | 2006-09-05 |
| CA2405190A1 (en) | 2003-03-28 |
| HUP0203176A2 (hu) | 2004-07-28 |
| DE60204403T2 (de) | 2006-05-04 |
| PL204141B1 (pl) | 2009-12-31 |
| CA2405190C (en) | 2010-11-09 |
| US20070196468A1 (en) | 2007-08-23 |
| US7691409B2 (en) | 2010-04-06 |
| US20030091624A1 (en) | 2003-05-15 |
| AU2002301259C1 (en) | 2009-07-23 |
| PT1297825E (pt) | 2005-08-31 |
| HU0203176D0 (enExample) | 2002-11-28 |
| DE60204403D1 (de) | 2005-07-07 |
| MXPA02009570A (es) | 2004-07-30 |
| ES2243664T3 (es) | 2005-12-01 |
| RU2362569C2 (ru) | 2009-07-27 |
| AU2002301259B2 (en) | 2009-01-22 |
| BR0204001A (pt) | 2003-09-16 |
| ATE296619T1 (de) | 2005-06-15 |
| DK1297825T3 (da) | 2005-09-26 |
| EP1297825B1 (en) | 2005-06-01 |
| NZ521657A (en) | 2004-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5390073A1 (es) | Forma de dosificacion oral solida de simeticona | |
| MXPA05007643A (es) | Metodo para producir una forma farmaceutica oral con desintegracion inmediata y liberacion de ingrediente activo. | |
| BR0215193A (pt) | Formulações de azitromicina diretamente compressìveis | |
| CY1118211T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν ενωσεις λανθανιου | |
| SV2002000342A (es) | Inhibidor de la glucogeno fosforilasa ref. pc.10753/20151/bb | |
| CL2008002407A1 (es) | Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04). | |
| BRPI0519212A2 (pt) | composiÇÕes farmacÊuticas de desintegraÇço oral contendo agentes de manifestaÇço sensorial | |
| CL2004002017A1 (es) | Forma de dosificacion termoformada a prueba de abuso que contiene (a) uno o mas principios activos susceptibles de abuso, (b) opcionalmente sustancias auxiliares, (c) al menos un polimero sintetico o natural de un grupo definido y (d) opcionalmente a | |
| BR0112054A (pt) | Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico | |
| PT1401501E (pt) | Composicoes farmaceuticas orais com libertacao modificada do ingrediente activo | |
| ATE350072T1 (de) | Parfümzusammensetzungen | |
| ES2182357T3 (es) | Nueva utilizacion de budesonide y formoterol. | |
| UY27296A1 (es) | Composición farmacéutica que contiene mosaprida y pancreatina | |
| BR0311663A (pt) | Preparação em forma de pelìcula contendo uma substância ativa, uso de uma preparação e processo para a produção de uma preparação | |
| NO20034863L (no) | Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser | |
| ECSP034826A (es) | Método para fabricar una composición farmacéutica de dosis baja | |
| BR0202491A (pt) | Forma de dosagem de núcleo macio, de revestimento frágil | |
| BR0111868A (pt) | Composições farmacêuticas | |
| JP2003508328A5 (enExample) | ||
| BRPI0509053A (pt) | composição farmacêutica anidra e uso de um agente siliconado e de uma composição | |
| EA200701107A1 (ru) | Твердая фармацевтическая композиция, содержащая валсартан | |
| SG158869A1 (en) | A tetracycline metal complex in a solid dosage form | |
| BR0317623A (pt) | Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram | |
| BR0314787A (pt) | Forma de dosagem de liberação modificada | |
| EP1570842A3 (en) | Composition containing chondroitin sulphate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |